Propanc Biopharma, Inc. announced the pricing of an underwritten public offering of 1,000,000 shares of common stock at $4.00 per share, expected to yield $4 million. The offering includes a 45-day option for the underwriter to purchase up to 150,000 additional shares. The Company received approval to list its common stock on the Nasdaq Capital Market starting August 15, 2025. The stock will trade under the symbol “PPCB.” D. Boral Capital LLC and Craft Capital Management LLC are acting as book running managers for the offering, with a registration statement declared effective by the SEC on August 13, 2025.

Propanc Biopharma, Inc. is developing a novel approach to preventing recurrence and metastasis of solid tumors using pancreatic proenzymes. The company’s proenzyme therapy is based on the theory that pancreatic enzymes stimulate biological reactions that could be the body’s primary defense against cancer. Forward-looking statements in the press release emphasize the company’s expectations and plans regarding market position, product development, and relations with partners and investors. Investors can find more information on the company’s website or contact Propanc Biopharma directly for further inquiries.

Read more at GlobeNewswire: Propanc Biopharma Announces Nasdaq Uplisting and Pricing of